Clinical Trials

EGFR-mutant Non-small Cell Lung Cancer

NCT05110196 2025-12-03

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Phase 4 Completed

50 enrolled

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04926831 2025-10-16

Geometry-N

4 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04677595 2025-06-24

GeoMETry-C

37 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04427072 2025-05-16

GeoMETry-III

Phase 3 Terminated

22 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT04139317 2024-10-09

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

76 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT04323436 2024-10-09

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

31 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03484923 2024-06-18

PLATforM

196 enrolled 22 charts

Dermatologic

Melanoma

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

373 enrolled 34 charts 3 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT02159066 2024-03-05

LOGIC-2

158 enrolled 40 charts

Dermatologic

Melanoma

NCT02795429 2023-07-03

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Phase 1/2 Completed

89 enrolled 37 charts

Gastrointestinal

Liver Neoplasms

NCT02335944 2023-06-18

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Phase 1/2 Terminated

177 enrolled 48 charts

Carcinoma, Non-Small-Cell Lung

NCT02323126 2022-02-28

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

64 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung

NCT03647488 2022-01-24

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

18 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

161 enrolled 32 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01546428 2020-12-19

A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors

44 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT02474537 2020-12-10

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

31 enrolled

Hepatic Impairment

NCT02520752 2020-12-10

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

37 enrolled

Other solid neoplasm

cMET-dysregulated Advanced Solid Tumors

NCT02626234 2020-12-10

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

32 enrolled

Other solid neoplasm

cMET-dysregulated Advanced Solid Tumors

NCT04460729 2020-12-03

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Phase 2 Withdrawn

GastrointestinalHead & Neck

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02205398 2019-01-22

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Phase 1 Terminated

13 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01870726 2018-05-30

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

Phase 1/2 Terminated

43 enrolled 22 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01072266 2017-11-22

A Dose-escalation Study in Subjects With Advanced Malignancies